Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

Returns on capital

Mereo BioPharma Group plc management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-102.4%

avg 40.6%

ROIC

-91.5%

avg -48.9%

ROA

-91.2%

avg -58.2%

Analysis

ROA is currently the strongest return metric at -91.2% versus its period average of -58.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Denise Scots-Knight

Co-Founder, Chief Executive Officer & Executive DirectorUSD 686.84K67345.00K0.22%

Charles Sermon

Co-Founder, General Counsel, Business Development & Company SecretaryUSD 536.44K57105.25K0.07%

Christine Fox

Chief Financial OfficerUSD 497.2K45——

Jackie Parkin

Senior Vice President & Therapeutic Head—68——

John A. Lewicki

Chief Scientific Officer—7446.64K0.03%

Bo Kara

Senior Vice President and Head of Pharmaceutical Development & CMC————

Alexandra Hughes-Wilson

Chief of Patient Access & Commercial Planning—5561.25K0.04%

Bal Lally

VP & Head of HR————

Bharti Navsariwala

VP & Head of Regulatory Affairs————

Compensation is shown in the reported currency; data updated Sep 26, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Feb 1, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
+179.9% (5yr)1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Forward estimates point to Revenue at +179.9% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does Mereo BioPharma Group plc compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about MREO's management, answered from reported figures.

Who manages MREO?

Mereo BioPharma Group plc (MREO) lists 9 active executives. The top listed executive is Denise Scots-Knight, Co-Founder, Chief Executive Officer & Executive Director.

Are MREO insiders buying or selling?

Recent insider activity shows net selling of $2.44M.